Skip to Main Content

Author Details

Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
2009
47
19
PMIDPaper TitleJournal TitlePublished Year
38049664The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Nat Genet2024
36879929Osimertinib in NSCLC With Atypical <i>EGFR</i>-Activating Mutations: A Retrospective Multicenter Study.JTO Clin Res Rep2023
34480094NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.Br J Cancer2022
35353542Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.Sci Transl Med2022
35074229In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"J Thorac Oncol2022
35183775Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.J Thorac Oncol2022
34523767Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.Oncologist2022
34516023Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.Oncologist2022
34455066Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.J Thorac Oncol2022
34165651Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.Curr Treat Options Oncol2021
33588109Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.J Thorac Oncol2021
34036220Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.JCO Precis Oncol2021
34088726Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.Clin Cancer Res2021
34001994A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer.NPJ Precis Oncol2021
31548343Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.Clin Cancer Res2020
33007380Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Ann Oncol2020
32822576Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.Cell2020
32846060Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.N Engl J Med2020
32642202Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.J Thorac Dis2020
32366673Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.Clin Cancer Res2020
32540409Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.J Thorac Oncol2020
29529128Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.Ann Oncol2019
30992280Engineering Multidimensional Evolutionary Forces to Combat Cancer.Cancer Discov2019
30579546A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.J Thorac Oncol2019
30553716Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.Clin Lung Cancer2019
30538120Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.Cancer Res2019
29251525The importance of the initial response to cancer treatment in predicting longer overall survival.Expert Rev Clin Pharmacol2018
30104724RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.Nat Cell Biol2018
30197261First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.Clin Lung Cancer2018
30268698Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.J Thorac Oncol2018
29636358Resistance Mechanisms to Targeted Therapies in <i>ROS1</i><sup>+</sup> and <i>ALK</i><sup>+</sup> Non-small Cell Lung Cancer.Clin Cancer Res2018
29599410Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.Clin Cancer Res2018
29708132The evolving understanding of immunoediting and the clinical impact of immune escape.J Thorac Dis2018
29045514Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.Ann Oncol2017
35172482Acral Lentiginous Melanoma Harboring a <i>ROS1</i> Gene Fusion With Clinical Response to Entrectinib.JCO Precis Oncol2017
29106415Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Nat Genet2017
26725180A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.J Thorac Oncol2016
27910964Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.Drugs Today (Barc)2016
27378174Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.Clin Lung Cancer2016
25932381Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer.Cancer Treat Commun2015
24065379Fungating mass as first presentation of advanced breast cancer.J Gen Intern Med2014
25228144The minority report: targeting the rare oncogenes in NSCLC.Curr Treat Options Oncol2014
24721799Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.J Am Heart Assoc2014
23439776Gender-related variation in the clinical presentation and outcomes of critical limb ischemia.Vasc Med2013
24518373Treatment paradigms in advanced non-small-cell lung cancer.Clin Adv Hematol Oncol2013
19220256Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.BJU Int2009
19503594Systematic identification of balanced transposition polymorphisms in Saccharomyces cerevisiae.PLoS Genet2009
  • 1 - 47 of 47

Recommended Authors

Zorawar S Noor
David Geffen School of Medicine at university of california los angeles
Career Start Year 2016
Number of shared co-authors 0
Amy L Cummings
university of california los angeles School of Medicine
Career Start Year 2014
Number of shared co-authors 4
Arjan Gower
David Geffen School of Medicine at University of California at Los Angeles
Career Start Year 2014
Number of shared co-authors 0
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 2012
Number of shared co-authors 4
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 0
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 2
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Gareth Rivalland
Auckland City Hospital
Career Start Year 2010
Number of shared co-authors 1
Puey Ling Chia
Lee Kong Chian School of Medicine, Nanyang Technological University
Career Start Year 2009
Number of shared co-authors 1
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 1
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 4
Paul Wheatley-Price
The Ottawa Hospital Research Institute
Career Start Year 2005
Number of shared co-authors 1
Edward B Garon
David Geffen School of Medicine, University of California Los Angeles
Career Start Year 2005
Number of shared co-authors 6
Aaron Lisberg
Jonsson Comprehensive Cancer Center, university of california los angeles
Career Start Year 2002
Number of shared co-authors 2
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 5
Fiona Blackhall
The University of Manchester
Career Start Year 2000
Number of shared co-authors 5
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 9
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 6
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 4
Cheryl Ho
University of British Columbia
Career Start Year 1995
Number of shared co-authors 2
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 15
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 10
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 3
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 7
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 14
Pasi A J??nne
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 11
Roy S Herbst
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 10
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 1981
Number of shared co-authors 8
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 8
Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Career Start Year 1978
Number of shared co-authors 5

Collaborators

Collin M Blakely
University of California san francisco
Co-authored papers 12
Trever G Bivona
University of California san francisco
Co-authored papers 12
Victor Olivas
University of California san francisco
Co-authored papers 5
Matthew A Gubens
University of California san francisco
Co-authored papers 4
Alexander Drilon
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Gideon M Blumenthal
Oncology Center of Excellence
Co-authored papers 3
Ezra A Amsterdam
University of California (Davis) Medical Center
Co-authored papers 2
Charles Swanton
Francis Crick Institute
Co-authored papers 2
David M Jablons
University of California, USA Cardiovascular Research Institute san francisco
Co-authored papers 2
Steve E Braunstein
University of California san francisco
Co-authored papers 2
Erqi L Pollom
Stanford University
Co-authored papers 2
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 1
Sean E Hanlon
Drew University, National Institutes of Health, Rutgers University New Brunswick, University of North Carolina at Chapel Hill
Co-authored papers 1
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 1
William A Robinson
National Centre for Asbestos Related Diseases, University of Western Australia
Co-authored papers 1
Pier Selenica
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Joanna O Mieczkowska
Renaissance Computing Institute, University of North Carolina at Chapel Hill
Co-authored papers 1
William L Brown
University of Minnesota
Co-authored papers 1
Eric W Ganko
University of North Carolina at Chapel Hill
Co-authored papers 1
Jason D Lieb
The University of Chicago
Co-authored papers 1
Frederick G Mann
Stowers Institute for Medical Research, USA Howard Hughes Medical Institute
Co-authored papers 1
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 1
Dirk De Ruysscher
Maastro Clinic
Co-authored papers 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Co-authored papers 1
Hazel X Ang
Duke University School of Medicine
Co-authored papers 1
Antonio Jimeno
University of Colorado School of Medicine
Co-authored papers 1
Dana S Neel
Stanford University School of Medicine
Co-authored papers 1
Subba R Digumarthy
Massachusetts General Hospital, USA Harvard Medical School
Co-authored papers 1
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Co-authored papers 1
Nilanjana Chatterjee
Chittaranjan National Cancer Institute
Co-authored papers 1
Release 1.2